Showing 661-670 of 805 results for "".
- Aerpio Pharmaceuticals Presents New Data Showing Potential of Topical Ocular Formulation of AKB-9778 When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-presents-new-data-showing-potential-of-topical-ocular-formulation-of-akb-9778-when-combined-with-prostaglandin/2477289/Aerpio Pharmaceuticals announced that Kevin Peters, MD, Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a phase 1b trial showing the potential of a topical ocular formulation of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower IOP with minimal con
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- New Chair, Members Named to Eversight Board of Directorshttps://modernod.com/news/new-chair-members-named-to-eversight-board-of-directors/2477217/Eversight announced that two new members and a new chair have been named to its Board of Directors, effective Jan. 1, 2020. Joining the Eversight Board of Directors are Carolyn Welsh, Vice President & Chief Clinical Officer, NJ Sharing Network; and Mahmoud N. Ghazzi, MD, PhD, MPH, an e
- Largest Study of Chinese Americans Uncovers Unique Risk Factors for Visual Impairmenthttps://modernod.com/news/largest-study-of-chinese-americans-uncovers-unique-risk-factors-for-visual-impairment/2477019/CHA Hollywood Presbyterian Medical Center (CHA HPMC) announced publication of a study by Rohit Varma, MD, MPH, director of its Southern California Eye Institute, assessing risk factors for vision impairment in Chinese Americans. The largest study on Chinese Americans to date, “Factors Associated
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv